Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ

Department of Gastroenterology, Division of Internal Medicine, University of Manitoba, Winnipeg, Man.
Canadian Medical Association Journal (Impact Factor: 5.81). 09/2008; 179(4):319-26. DOI: 10.1503/cmaj.071330
Source: PubMed

ABSTRACT The use of proton pump inhibitors has been associated with an increased risk of hip fracture. We sought to further explore the relation between duration of exposure to proton pump inhibitors and osteoporosis-related fractures.
We used administrative claims data to identify patients with a fracture of the hip, vertebra or wrist between April 1996 and March 2004. Cases were each matched with 3 controls based on age, sex and comorbidities. We calculated adjusted odds ratios (OR) for the risk of hip fracture and all osteoporosis-related fractures for durations of proton pump inhibitor exposure ranging from 1 or more years to more than 7 years.
We matched 15 792 cases of osteoporosis-related fractures with 47 289 controls. We did not detect a significant association between the overall risk of an osteoportic fracture and the use of proton pump inhibitors for durations of 6 years or less. However, exposure of 7 or more years was associated with increased risk of an osteoporosis-related fracture (adjusted OR 1.92, 95% confidence interval [CI] 1.16-3.18, p = 0.011). We also found an increased risk of hip fracture after 5 or more years of exposure (adjusted OR 1.62, 95% CI 1.02-2.58, p = 0.04), with even higher risk after 7 or more years exposure (adjusted OR 4.55, 95% CI 1.68-12.29, p = 0.002).
Use of proton pump inhibitors for 7 or more years is associated with a significantly increased risk of an osteoporosis-related fracture. There is an increased risk of hip fracture after 5 or more years exposure. Further study is required to determine the clinical importance of this finding and to determine the value of osteoprotective medications for patients with long-term use of proton pump inhibitors.

Download full-text


Available from: Colleen Metge, Aug 17, 2015
  • Source
    • "PPIs have been widely used since their introduction in the late 1980s. Several large observational studies suggest that PPI use is associated with a modest increase in osteoporotic fracture risk [Yang et al. 2006; Yu et al. 2008; Vestergaard et al. 2006b; Targownik et al. 2008]. Based on these and two other studies, the US Food and Drug Administration revised labeling for PPIs in May 2010 to include information about the potential risk of hip, spinal, or radial fractures. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug-induced osteoporosis is a significant health problem and many physicians are unaware that many commonly prescribed medications contribute to significant bone loss and fractures. In addition to glucocorticoids, proton pump inhibitors, selective serotonin receptor inhibitors, thiazolidinediones, anticonvulsants, medroxyprogesterone acetate, aromatase inhibitors, androgen deprivation therapy, heparin, calcineurin inhibitors, and some chemotherapies have deleterious effects on bone health. Furthermore, many patients are treated with combinations of these medications, possibly compounding the harmful effects of these drugs. Increasing physician awareness of these side effects will allow for monitoring of bone health and therapeutic interventions to prevent or treat drug-induced osteoporosis.
    Therapeutic advances in musculoskeletal disease 10/2014; 6(5):185-202. DOI:10.1177/1759720X14546350
  • Source
    • "A study conducted in Canada determined that after seven years of continuous exposure to a PPI, there was a statistically significant increase in osteoporosis-related fractures, and an increase risk of hip fracture after five years. [9] As bone mineralization and resorption takes many years, and because of the subtle effect that proton pump inhibitors have on bone mineralization, several years may be required before it has a measurable clinical outcome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Proton pump inhibitors (PPI) are a relatively new class of potent gastric acid-suppressing agents that are used in the treatment of multiple gastrointestinal (GI) disorders. As with any medication it is important that PPIs should only be prescribed when appropriate, and mainly for FDA-approved indications. The improper use of proton pump inhibitors can lead to unwanted adverse effects and increase the chances for drug induced disease, such as gastric cancer. There is some recent evidence indicating that improper use of PPI is rising. Findings from our literature review and clearly suggest that PPI’s are being abused through overuse, and the various unintentional consequences of their overuse; not only to the individuals taking the medications, but also the additional cost incurred by the healthcare system.
    03/2013; 3(2). DOI:10.9790/3013-32202529
  • Source
    • "Both the dose and the duration of proton pump inhibitors were associated with higher risk of hip fracture in patients in the General Practitioners' Research Database (Yang et al. 2006). Use of a proton-pump inhibitor for 7 or more years was associated with double the risk of osteoporotic fracture and a 5-times higher risk of hip fracture, and use for 5 or more years was associated with double the risk of hip fracture (Targownik et al. 2008). Another study found that use of a proton-pump inhibitor in the previous year was associated with increased fracture risk (18%, 45%, and 60% higher odds for overall fracture, hip fracture, and spine fracture risk, respectively) (Vestergaard et "
    [Show abstract] [Hide abstract]
    ABSTRACT: There have been no published studies assessing the possible association of medical comorbidities with periprosthetic fracture risk. We therefore assessed whether medical comorbidity is associated with risk of periprosthetic fractures after total hip replacement (THR). We used prospectively collected data from 1989-2008 in the Mayo Clinic Total Joint Registry for 2 cohorts: primary THR and revision THR. The main variables of interest were Deyo-Charlson comorbidities at the time of surgery. Outcome of interest was p ostoperative periprosthetic fracture at postoperative day 1 onwards. Multivariable Cox regression models were additionally adjusted for age, sex, body mass index, American Society of Anesthesiology (ASA) class, and operative diagnosis. We identified 14,065 primary THRs and 6,281 revision THRs with mean follow-up times of 6.3 and 5.6 years, respectively. There were 305 postoperative periprosthetic fractures in the primary THR cohort and 330 in the revision THR cohort. In patients who underwent primary THR, 2 comorbidities were associated with higher risk of periprosthetic fracture: peptic ulcer disease with adjusted hazard ratio of 1.5 (95% CI: 1.1-2.2) and heart disease with adjusted hazard ratio of 1.7 (CI: 1.2-2.4). In patients with revision THR, peptic ulcer disease was associated with a higher adjusted risk of periprosthetic fracture, 1.6 (CI: 1.1-2.3). Peptic ulcer disease and heart disease in primary THR patients and peptic ulcer disease in revision THR patients were associated with higher postoperative periprosthetic fracture risk. Further studies are needed to understand whether disease severity or specific medications used for treatment, or both, are responsible for this association. This may allow identification of modifiable factors.
    Acta Orthopaedica 08/2012; 83(4):353-9. DOI:10.3109/17453674.2012.717844 · 2.45 Impact Factor
Show more